Last reviewed · How we verify

NCT03780738: VaRALAD

A Validation Study of The Relationship Between ALDH2 and Aortic Dissection

Status unknown Last updated 19 December 2018
What this trial tests

trial in Aortic Dissection in 200 participants. Status unknown.

Timeline
1 October 2018
Primary endpoint
30 September 2019
30 September 2019

Quick facts

Lead sponsorQilu Hospital of Shandong University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date1 October 2018
Primary completion30 September 2019
Estimated completion30 September 2019
Sites1 location across China

Conditions studied

Sponsor

Qilu Hospital of Shandong University

Who can join

Eligibility, any sex, with Aortic Dissection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to validate the impact of ALDH2 Glu504Lys polymorphism on aortic dissection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aortic Dissection

Currently open trials in the same condition.

Other Qilu Hospital of Shandong University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03780738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing